Audit: QRS - Carnivore Diet for Health & Longevity
Audit conducted on 25/06/2026 00:58 using AI4L / Opus 4.8
Summary
| Items | Count |
|---|---|
| Total | 91 |
| Passed | 83 |
| Failed | 0 |
| N/A | 8 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All content traces to the ER (Conclusion, Expected Benefits, Risks, Protocol, Monitoring, Key Interactions & Contraindications). |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | At-a-glance “rests on no controlled trials”, “evidence remains thin and unsettled” mirrors ER Conclusion. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening detected. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. | 🟢 | Contraindications, interactions, benefits, and risks map to their corresponding ER sections. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | QRS introduces no PMIDs, NCTs, expert names, or brands. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions added. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s objective, unsettled-evidence framing. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Maintained throughout. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents evidence, not prescriptions. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | No directive medical advice; footer disclaimer present. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | Information-presenting voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain language used; technical terms glossed where present. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Compact cells and bullets throughout. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | No direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing matches risk-aware adult audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Consistent with content. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Not general-population framed. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | Risk/benefit weighting consistent with ER. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging”. | 🟢 | “Longevity”/”healthspan” used; no “anti-aging”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language. | 🟢 | Formal terminology used. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified (card/section headings, gate headings, tier labels, Monitoring column headers). | 🟢 | “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”, “Contraindications”, “Key Interactions”, tier labels, and “Marker/Target/Why” all intact. |
| 3.2 | All “…” from the [qrs_template] are present in the QRS. | 🟢 | All expected spans present (67 var spans incl. 9 marker rows). |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Template internal-link spans (website=”…”) left untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. | N/A | No source ER section is empty. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Benefit/risk tier labels and protocol labels match ER. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | Labels consistent with ER. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). | 🟢 | No emoji indicators in QRS body. |
| 4.5 | The QRS is designed to render on one A4 page. Any section with more content than fits is condensed, not extended onto a second page. | 🟢 | Content condensed; single-page layout preserved. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Metadata comment is first element after doctype. |
| 5.2 | Inside that HTML comment the YAML block is delimited by an opening “—” and a closing “—”. | 🟢 | Delimited correctly (lines 3 and 13). |
| 5.3 | The metadata is not visible in any rendered view of the QRS. | 🟢 | Enclosed in HTML comment. |
| 5.4 | All frontmatter values are trimmed; no surrounding quotes unless required by YAML. | 🟢 | Only “duration” quoted (contains colon); others clean. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]”. | 🟢 | er_filename: carnivore_diet_2026-0625-0002_Opus_ER.md. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”. | 🟢 | qrs_prompt_version: 26.5.18 matches QRS.md. |
| 5.7 | Creation date and time stated as “qrs_creation_date: [YYYY-MMDD-HHMM]”. | 🟢 | qrs_creation_date: 2026-0625-0055. |
| 5.8 | The nickname of the AI is stated as “qrs_creator_ai_nickname”. | 🟢 | qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname is a single-word model name without version. | 🟢 | “Opus”. |
| 5.10 | The full name of the AI is stated as “qrs_creator_ai_fullname”. | 🟢 | qrs_creator_ai_fullname: Opus 4.8. |
| 5.11 | The full name consists of the nickname plus version number and no additional qualifier. | 🟢 | “Opus 4.8”. |
| 5.12 | The filename of the document is stated as “qrs_filename”. | 🟢 | qrs_filename: carnivore_diet_2026-0625-0002_Opus_QRS.html. |
| 5.13 | All frontmatter values are trimmed; no surrounding quotes unless required by YAML. | 🟢 | Values clean and consistent. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] followed by “ - Quick Reference Sheet”, HTML-entity-encoded as needed. | 🟢 | “Carnivore Diet for Health & Longevity - Quick Reference Sheet”. |
| 6.2 | [header_topic] is set to the [canonical_topic], HTML entities encoded as needed. | 🟢 | “Carnivore Diet for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]. | 🟢 | 06/25/2026 from 2026-0625-0055. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname]. | 🟢 | “Opus 4.8”. |
| 6.5 | No additional header content appears (no badge, version stamp, AKA line, source-AI attribution, audit date, or variant marker). | 🟢 | Header limited to title and standard subline. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is a dense, execution-oriented summary of the ER Conclusion section. |
🟢 | Condenses the ER Conclusion. |
| 7.2 | [at_a_glance] is no longer than 60 words. | 🟢 | 54 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Weight/glycemic/symptom relief, elimination effect, fiber loss, cholesterol rises, meat-cancer links, thin/unsettled all map to ER. |
| 7.4 | It DOES NOT use acronyms or technical classifications requiring specialist knowledge. | 🟢 | Plain language; “blood-sugar control” used instead of HbA1c, etc. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values). | 🟢 | No trials cited. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results. | 🟢 | No statistics cited. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section. |
🟢 | Derived from the “Populations who should avoid” bullet. |
| 8.2 | [stop_items] represent the Contraindications from the ER. | 🟢 | CKD, familial hypercholesterolemia, eating-disorder history, pregnancy, prior DKA, gout, hereditary hemochromatosis — all 7 present. |
| 8.3 | Individual [stop_items] are formatted as <li></li>. | 🟢 | Each item is an <li>. |
| 8.4 | Items are as concise as possible; no trailing explanations or content after a dash. | 🟢 | Concise; no trailing clauses. |
| 8.5 | Parenthetical qualifiers from the ER bullet are preserved, kept concise. | 🟢 | “(eGFR <60)” preserved. |
| 8.6 | When the ER uses ranking notation inside parens, normalize to a plain comma-separated list. | 🟢 | No ranking notation present; items are plain. |
| 8.7 | If no [stop_items] are present the section is left empty. | N/A | Contraindications are present. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section. |
🟢 | Derived from the interaction bullets. |
| 9.2 | [caution_items] represent the Key Interactions, excluding any already listed as Contraindications. | 🟢 | Glucose-lowering meds, BP/diuretics, warfarin, antacids/NSAIDs, iron/vitamin A supplements, SGLT2 inhibitors; no overlap with contraindications. |
| 9.3 | Individual [caution_items] are formatted as <li></li>. | 🟢 | Each item is an <li>. |
| 9.4 | Items are as concise as possible; no trailing explanations or content after a dash. | 🟢 | Concise; mechanistic detail stripped. |
| 9.5 | Parenthetical qualifiers (example drug lists, etc.) are preserved, kept concise. | 🟢 | Example drugs (glipizide, glibenclamide, ibuprofen, naproxen, canagliflozin, empagliflozin, dapagliflozin) preserved. |
| 9.6 | When the ER uses ranking notation inside parens, normalize to a plain comma-separated list. | 🟢 | No ranking notation; lists are plain. |
| 9.7 | If no [caution_items] are present the section is left empty. | N/A | Key Interactions are present. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section. |
🟢 | Derived from “Standard approach as used by leading proponents”. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section. |
🟢 | Foods (animal only), Intake (eat to satiety), Meal frequency (1–3/day). |
| 10.3 | If less than three distinct actionable aspects are mentioned, unused sets are left empty and invisible. | N/A | Three distinct actionable aspects are present. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All three cells fully populated from the ER. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER. | 🟢 | Weight & appetite (1–2 weeks), Metabolic markers (weeks), Fat-adaptation (3–6 weeks). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit. | 🟢 | Weight loss and glycemic control are the High-tier benefits, ordered first. |
| 11.3 | If less than three distinct time-to-effect aspects are mentioned, unused sets are left empty and invisible. | N/A | Three distinct aspects are present. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All three cells populated from ER “Time to effect”. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely. | N/A | The ER provides time-to-effect information. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section. |
🟢 | Tiers mirror the ER Expected Benefits. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]. | 🟢 | All four populated. |
| 12.3 | Items are as concise as possible; no explanations, effect sizes, qualifiers, attributions, citations, or mechanisms. | 🟢 | Concise; magnitudes/mechanisms stripped. |
| 12.4 | Parenthetical content is stripped, NOT preserved. | 🟢 | No parentheticals carried over. |
| 12.5 | If no items of a specific sub-section are present the respective span is set to display=none. | N/A | All four benefit tiers have content in the ER. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section. |
🟢 | Tiers mirror the ER Risks section. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]. | 🟢 | All four populated. |
| 13.3 | Items are as concise as possible; no explanations, effect sizes, qualifiers, attributions, citations, or mechanisms. | 🟢 | Concise; magnitudes stripped. |
| 13.4 | Parenthetical content is stripped, NOT preserved. | 🟢 | No parentheticals carried over. |
| 13.5 | If no items of a specific sub-section are present the respective span is set to display=none. | N/A | All four risk tiers have content in the ER. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section. |
🟢 | Derived from the ER lab-tests table. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed. |
🟢 | All 9 biomarkers (LDL, ApoB, HbA1c, fasting glucose, eGFR/creatinine, uric acid, electrolytes, vitamin C, vitamin A/iron) listed with matching targets. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER. | 🟢 | “Baseline, 4–8 weeks, 3 months, then every 6–12 months…” matches ER. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section. |
🟢 | Derived from the ER qualitative-markers list. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed. |
🟢 | All 6 qualitative markers listed verbatim. |
Issues 25/06/2026 00:58
Pass rate 100.00%. No issues found.